Cartalax vs TB-500
Emerging vs Well Studied
compatible Distinct action pathways; may complement effects.
Molecular Data
Cartalax TB-500
Weight ~350 Da 4,963.44 Da
Half-life Minutes (short peptide); effects persist via epigenetic changes ~2 hours
Chain 3 amino acids 43 amino acids
Type Tripeptide Thymosin fragment
Key Benefits
Cartalax
01 Joint and connective tissue support
02 Potential anti-aging effects on fibroblasts
03 Cartilage regeneration support
04 Established safety profile in Russian clinical practice
TB-500
01 Superior systemic tissue repair
02 Accelerated muscle, tendon, and ligament healing
03 Enhanced cell migration and angiogenesis
04 Comprehensive regenerative effects
05 Neuroprotective properties
Dosing Protocols
Cartalax
100-200mcg oral (1-2 capsules) or 700-1400mcg injectable / 1-2 times daily with meals (oral) or once daily (injectable)
Tissue Regeneration 700-1400mcg (10-20mcg/kg) Daily
TB-500
2-5mg per injection (higher doses for serious injuries) / 2-3x weekly (e.g., Monday, Wednesday, Friday)
General tissue repair 2-3mg 2x weekly
Serious injury recovery 4-5mg 3x weekly
Athletic enhancement 2-3mg 2x weekly
Chronic conditions 3-4mg 2-3x weekly
Maintenance 2mg 1-2x weekly
Post-surgical recovery 3-5mg 3x weekly
Side Effects
Cartalax
No reported side effects in Russian clinical use when taken properly
Well-tolerated in elderly patients
TB-500
Generally minimal side effects
Possible mild injection site reactions
Temporary fatigue in some users
Contraindications
Pregnancy and breastfeeding
Active cancer (theoretical proliferation risk)
Active cancer treatment (due to angiogenic effects)
Pregnancy or breastfeeding
Immunosuppressive medications (consult provider)
WADA prohibited for competitive athletes
Research Evidence
Cartalax TB-500
Status Emerging Well Studied
References 4 studies 4 studies
Latest — March 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.